Clinical Trials and Research References

Preclinical, Weight, Organ, and Safety Study Groups

Every clinical statistic, sample size, hazard ratio, and pharmacokinetic figure cited across Semaglutide New Mexico comes from four functional groups of peer-reviewed literature. First, preclinical and pharmacological papers—specifically the 2020 JCI Insight rodent brain mapping study, the 2024 Current Issues in Molecular Biology mechanism review, and the 2024 StatPearls reference chapter—establish structural homology with human GLP-1 (~94%), oral SNAC bioavailability (~0.4-1%), elimination half-life (~1 week, ~5 weeks in circulation), and rodent appetite nuclei.

Second, the weight-management trials include STEP 1 in adults (2021, n=1,961), STEP 5 over 104 weeks (2022), STEP TEENS in adolescents (2022), and the head-to-head SURMOUNT-5 comparison with tirzepatide (2025, n=751). Third, the organ-outcome trials encompass SUSTAIN-6 in type 2 diabetes (2016, n=3,297), SELECT in cardiovascular disease (2023, n=17,604), STEP-HFpEF in heart failure (2023), FLOW in chronic kidney disease (2024, n=3,533), and ESSENCE in biopsy-confirmed MASH (2025, n=1,197). Fourth, the 2025 JAMA Psychiatry alcohol trial (n=48) and the 2021 Frontiers in Endocrinology safety review document alcohol self-administration outcomes and adverse events.